• 1
    Meade TW, Brozovic MM, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WR, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 328: 5337.
  • 2
    Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 10769.
  • 3
    Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799809.
  • 4
    Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and the risk of peripheral arteriosclerosis. Lancet 1992; 339: 6935.
  • 5
    Iacoviello L, Di Castelnuovo A, De Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 7985.
  • 6
    Reitsma PH. No praise for folly: genomics will never be useful in arterial thrombosis. J Thromb Haemost 2007; 5: 4547.
  • 7
    Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 6518.
  • 8
    Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D. The association of Factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost 2010; 8: 211621.
  • 9
    Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 111722.
  • 10
    Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci PM. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern. Thromb Haemost 2002; 88: 6901.
  • 11
    Kleinbaum DG, Kupper LL, Morgenstern H (1982). Epidemiological Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold.
  • 12
    Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, Von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, Van Duijn C et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med 2009; 150: 20615.
  • 13
    Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993; 2: 299303.
  • 14
    Sud S, Douketis J. ACP Journal Club. The devil is in the details...or not? A primer on individual patient data meta-analysis. Ann Intern Med 2009; 151: JC12.